Please read and agree to the terms and conditions of this site.
@xconomy.com 3 years ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com 3 years ago
Grail Files to Go Public; 5 More Life Science Firms Join the IPO Queue
@xconomy.com 4 years ago
CRISPR, CAR-T, Consolidation: Top Advanced Therapy Milestones of 2019
@xconomy.com 4 years ago
Bio Roundup: Ichnos Emerges, Beyond CAR-T, BridgeBio Bails & More
@xconomy.com 4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com 4 years ago
Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More
@xconomy.com 4 years ago
Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More
@xconomy.com 4 years ago
Bio Roundup: Michael Becker, Suzanne Eaton, Gene Therapy Moves & More
@xconomy.com 5 years ago
Pharma CEOs to Senate: We Will Lower Drug Prices if Rebates Go Away
@xconomy.com 5 years ago
Bio Roundup: Alzheimer’s Fail, Drug Price Plan, Gene Therapies & More
@xconomy.com 5 years ago
Notes from the JPM19 Vortex: Price Apocalypse, Celgene Fallout & More
@xconomy.com 5 years ago
ASH 2018: A Guide to the Latest for Blood-Borne Cancers and More